At a glance
| Drug family | GnRH antagonist |
|---|---|
| Approved purpose | Prevents premature LH surges |
| Clinical setting | Controlled ovarian hyperstimulation |
| Delivery | Subcutaneous injection |
| Treatment relationship | Used alongside ovarian-stimulation medicines |
Overview
Ganirelix is used together with gonadotropins during ovarian stimulation. Its purpose is to prevent the body from initiating ovulation too early while multiple follicles are developing. Clinical protocols balance suppression of an unwanted LH surge against continued follicular growth, with ultrasound and hormonal assessment informing decisions. Ganirelix is distinct from the medicines used to stimulate the ovaries and from the final maturation trigger. Although it can support the timing of IVF or related procedures, it does not resolve every cause of infertility or independently guarantee a successful pregnancy.
How it works
Ganirelix competitively antagonizes the GnRH receptor on pituitary gonadotroph cells. This produces rapid, reversible suppression of LH and FSH secretion without first stimulating the receptor. In a fertility cycle, externally administered FSH supports the ovaries while ganirelix limits premature endogenous LH release. Its mechanism is related to cetrorelix, but the molecules and their individual prescribing instructions are not identical.
What does ganirelix contribute to an IVF cycle?
Ganirelix helps preserve the planned timing of egg maturation and retrieval by suppressing an early LH surge. It is not itself an ovarian-stimulation medicine. The relevant outcome is safe coordination of the complete treatment cycle, rather than maximal suppression of every reproductive hormone.
Supporting sources [1]
What human evidence supports it?
A multicenter randomized phase III trial compared ganirelix with a long leuprolide protocol during controlled ovarian hyperstimulation. The clinical program evaluated premature LH surges, ovarian response, pregnancy outcomes and tolerability. These data support the approved reproductive setting and do not establish benefit for unrelated hormone or wellness goals.
What are the main precautions?
Hypersensitivity reactions, including anaphylaxis, require attention. Known or suspected pregnancy and relevant GnRH-related allergies are contraindications. Some needle shields may contain natural rubber or latex, depending on the product. Injection-site symptoms can occur, and ovarian hyperstimulation syndrome must still be monitored within the broader stimulation protocol.
Supporting sources [1]
Can ganirelix and cetrorelix simply be swapped?
Both block GnRH receptors, but a shared drug class does not make individual fertility schedules interchangeable. Product instructions and the timing of ovarian stimulation remain specific. Changes during a cycle require the fertility team’s assessment because incomplete suppression can interfere with planned egg retrieval.
Supporting sources [1]
Reading this profile
Jurisdiction: United States; indications and availability vary by formulation and country.. Molecular class: Synthetic decapeptide GnRH receptor antagonist.
This profile was written with AI-assisted research and checked against the linked sources. It has not been represented as a clinician’s review. Evidence summaries describe the cited studies and products; they do not establish that a separately purchased preparation is equivalent.
Sources & references
Follow the original material. Product labels define specific formulations and uses; trial registration describes a study and does not by itself establish benefit.
- Ganirelix acetate — current US prescribing information ↗Regulatory source · Checked 2026-10-27
- Efficacy and safety of ganirelix acetate versus leuprolide acetate in controlled ovarian hyperstimulation ↗Original research · Checked 2026-10-27